Abstract: The present invention is related to the use of a recombinant protein to induce interleukin 10 expression, wherein the protein is Taenia solium parasite recombinant calreticulin (rTsCRT) formulated in a physiologic glycosated solution orally or parenterally administered. The used methodology for rTsCRT expression and purification described in present invention, resulted in a recombinant protein expressed without post-translational modifications having regulatory immunological effects and capable of stimulating the mRNA transcription levels which codify for IL-4 and IL-10 cytokines. rTsCRT expression is conducted in an E. coli untagged system, though applicable to any expression system, whether prokaryote or eukaryote cells. The purpose of producing rTsCRT is to use it for treatment of local or systemic inflammatory diseases.

Abstract: The invention features compositions and methods for the detection of and differentiation between Taenia solium and/or Taenia saginata. Specifically, the invention features nucleic acid probes comprising specific repetitive sequences of T. solium and T. saginata. These sequences make it possible to distinguish, with a high level of sensitivity and specificity, the eggs of these species of Taenia, thus enabling the diagnosis of taeniasis and the identification of carriers of Taenia solium. The invention is of great importance in controlling spread of T. solium due to ingestion of infected pork and/or exposure to human carriers of T. solium, thus facilitating the eradication of human and swine cysticercosis. The invention is thus of great importance in supporting eradication of human and swine cysticercosis.